A version of this article appeared for the first time in the CNBC Healthy Returns newsletter, which brings the latest news of health care directly in your reception box. Subscribe here To receive future editions.
A wave of indignation sweeps the scientific and medical world after the decision of the Secretary of Health and Social Services Robert F. Kennedy Jr. Stop recommending covid-19 routine vaccines For healthy children and healthy pregnant women.
Kennedy, a prominent vaccination skeptic, said on Tuesday that the covid shooting had been withdrawn from the vaccination calendar recommended by the centers for Disease Control and Prevention for these groups.
“Last year, the Biden administration urged healthy children to get another cocovated shot, despite the absence of clinical data to support the repeated recall strategy in children,” Kennedy said in a video On X., he did not propose any scientific evidence to justify the change in recommendations.
This is Kennedy’s latest decision to change and potentially undermine vaccinations in the United States since he took the bar of the Ministry of Health and Social Services, which oversees federal agencies that regulate and recommend photos.
It comes a week after the Food and Drug Commissioner Marty Makary Administration establish stricter standards To approve photos for healthy Americans.
Some health experts say that the abandoned recommendation could have devastating consequences, especially for pregnant women and their babies.
Both are considered to be Higher risk of severe Complications of COVVI-19 infections, according to the CDC website. Who may include Premature work and birthHeart injury, blood clots and kidney lesions in pregnant women.
“As an ob-gyns who treat the patients every day, we have seen in the first hand how dangerous COVVI-19 infection can be during pregnancy and for newborns who depend on maternal antibodies of the protection vaccine,” said Steven Fleischman, president of the American College of Obstetricians and Gynecologists, in a press release.
He stressed that “science has not changed”.
“Following this announcement, we are worried about our patients in the future, who may be less likely to choose vaccination during pregnancy despite clear and final evidence demonstrating its advantage,” said Fleischman.
Studies have found This COVVI-19 vaccination reduces the risk of hospitalization of the virus for pregnant women and infants under 6 months of age.
Fleischman and other experts have also expressed their concerns as to whether patients will have access to vaccines following Kennedy’s decision. The CDC recommendation is crucial because it guides insurance schemes on shots at no cost for patients.
Medicare and Medicaid need the recommended vaccines to be free for patients. The affordable care law obliges private insurers to cover all the vaccines recommended by the CDC’s external committee of advisers and director of CDC vaccines. Children without insurance can obtain free recommended vaccines through the government’s vaccine program led by the government.
Pfizer And Modern invoice up to $ 150 per dose for their respective coated photos before insurance, according to CDC website.
“This decision could make more difficult for millions of Americans to access the vaccines they want for themselves and their families,” said Tina Tan, president of the Society for Infectious Diseases statement.
Tan added this process for Kennedy’s decision -making breaks with the previous one to leave the federal experts of experts publicly debate scientific evidence and vote on vaccination practices. A group of CDC external advisers generally gives vaccination advice to the agency director.
Trump’s candidate to lead the CDC, the acting director Susan Monarez, still needs confirmation from the Senate.
“This decision bypassing a well -established evidence -based process used to ensure the safety of vaccines and ignores the expertise of independent medical experts, including members of the CDC committees who examine the evidence concerning the vaccine to make recommendations for the fall,” said Sean O’Leary, President of the American Academy of Pediatric statement.
He added that the decision could “strip families of choice”, preventing those who want to vaccinate from taking photos.
Do not hesitate to send advice, suggestions, history ideas and data to Annika to annikakim.constantino@nbcuni.com.
Last in health care technology: Hinge Health is making his debut on the New York Stock Exchange
Reports Hinge Health Inc. on the New York Stock Exchange Prosecutor’s Office (NYSE) during the company’s initial public offer (IPO) in New York, United States, Thursday, May 22, 2025.
Michael Nagle | Bloomberg | Getty images
Have you heard this? It was the sound of the digital health sector breathing in a sigh of collective relief.
Digital physical therapy company Pivotal health made his debut on the New York Stock Exchange last week In The first major public outing in the sector in several years.
The wider market for technological stock market IPO has been in drought since the end of 2021, when the rise in inflation and the increase in interest rates have pushed investors outside risky assets. And in digital health, there has been practically no activity of Introduction on the stock market.
Hinge, founded in 2014, uses software to help patients treat acute musculoskeletal injuries and chronic pain, as well as to rehabilitation after remote surgery.
The action opened its doors at $ 39.25 Thursday, up 23% compared to its $ 32 IPO. It increased by 17% to $ 37.56 per share, bringing market capitalization to more than $ 3 billion. On Wednesday afternoon, shares are negotiated at more than $ 41.
Before his IPO, Hinge had raised more than a billion dollars to investors, including Insight Partners, Atomico, Tiger Global Management and Coatue Management.
Most analysts will officially launch the coverage of the title about 30 days after its beginnings. But Roth analysts shared some initial reflections on Hinge earlier this month, before becoming public. Above all, they did not participate in the offer, made a recommendation or initiate coverage in their report.
“We looked at the presentation of HNGE IPO Roadshow and were impressed by the AI products underlying the platform and the expansion of the care rate”, in particular beyond musculoskeletal conditions, analysts said in a note on May 16.
Hinge said revenues in his first quarter had increased by $ 123.8 million, compared to $ 82.7 million in the same period last year. The company said $ 117.3 million in revenue during its fourth quarter, up 44% compared to the same period in 2023.
Roth analysts said that the company’s recent fundamentals were encouraging, including its income and acceleration bills as well as its improved operational margins. Some of the risks confronted with the company include the competitive digital therapy landscape, its dependence on the data evaluated by peers and an overhang of regulation, they said.
After the beginnings of Hinge, another digital health company is preparing to join the fray. Omada Health filed an IPO earlier this month, although she has not yet shared more details on her expected prices or chronology.
Omada offers virtual care programs to support patients with chronic diseases such as prediabetes, diabetes and hypertension.
As we did with Hinge, we will follow this offer closely, so stay attentive for updates!
Do not hesitate to send advice, suggestions, history ideas and data to Ashley to ashley.capoot@nbcuni.com.
